|
1
|
Al-Brahim N and Asa SL: Papillary thyroid
carcinoma: An overview. Arch Pathol Lab Med. 130:1057–1062.
2006.PubMed/NCBI
|
|
2
|
Segovia Gomez I, Gallowitsch HJ, Kresnik
E, Kumnig G, Igerc I, Matschnig S, Stronegger WJ and Lind P:
Descriptive epidemiology of thyroid carcinoma in Carinthia,
Austria: 1984–2001. Histopathologic features and tumor
classification of 734 cases under elevated general iodination of
table salt since 1990: Population-based age-stratified analysis on
thyroid carcinoma incidence. Thyroid. 14:277–286. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Akslen LA, Haldorsen T, Thoresen SO and
Glattre E: Incidence pattern of thyroid cancer in Norway: Influence
of birth cohort and time period. Int J Cancer. 53:183–187. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Colonna M, Grosclaude P, Remontet L,
Schvartz C, Mace-Lesech J, Velten M, Guizard A, Tretarre B, et al:
Incidence of thyroid cancer in adults recorded by French cancer
registries (1978–1997). Eur J Cancer. 38:1762–1768. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Howe HL, Wingo PA, Thun MJ, Ries LA,
Rosenberg HM, Feigal EG and Edwards BK: Annual report to the nation
on the status of cancer (1973 through 1998), featuring cancers with
recent increasing trends. J Natl Cancer Inst. 93:824–842. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Davies L and Welch HG: Increasing
incidence of thyroid cancer in the United States, 1973–2002. JAMA.
295:2164–2167. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Churilla TM, Donnelly PE, Leatherman ER,
Adonizio CS and Peters CA: Total mastectomy or breast conservation
therapy? how radiation oncologist accessibility determines
treatment choice and quality: A SEER Data-base analysis. Breast J.
21:473–480. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schechter RB, Nagilla M, Joseph L, Reddy
P, Khattri A, Watson S, Locati LD, Licitra L, Greco A, Pelosi G, et
al: Genetic profiling of advanced radioactive iodine-resistant
differentiated thyroid cancer and correlation with axitinib
efficacy. Cancer Lett. 359:269–274. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Knauf JA, Ma X, Smith EP, Zhang L,
Mitsutake N, Liao XH, Refetoff S, Nikiforov YE and Fagin JA:
Targeted expression of BRAFV600E in thyroid cells of transgenic
mice results in PTCs that undergo dedifferentiation. Cancer Res.
65:4238–4245. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kundu A, Quirit JG, Khouri MG and
Firestone GL: Inhibition of oncogenic BRAF activity by
indole-3-carbinol disrupts microphthalmia-associated transcription
factor expression and arrests melanoma cell proliferation. Mol
Carcinog. 56:49–61. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Saugstad JA: MicroRNAs as effectors of
brain function with roles in ischemia and injury, neuroprotection,
and neurodegeneration. J Cereb Blood Flow Metab. 30:1564–1576.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nalysnyk L, Cid-Ruzafa J, Rotella P and
Esser D: Incidence and prevalence of idiopathic pulmonary fibrosis:
Review of the literature. Eur Respir Rev. 21:355–361. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sondermann A, Andreghetto FM, Moulatlet
AC, da Silva Victor E, de Castro MG, Nunes FD, Brandão LG and
Severino P: MiR-9 and miR-21 as prognostic biomarkers for
recurrence in PTC. Clin Exp Metastasis. 32:521–530. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoon S, An YS, Lee SJ, So EY, Kim JH,
Chung YS and Yoon JK: Relation between F-18 FDG uptake of PET/CT
and BRAFV600E mutation in PTC. Medicine (Baltimore). 94:e20632015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–8. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shen CH, Yuan P, Perez-Lorenzo R, Zhang Y,
Lee SX, Ou Y, Asara JM, Cantley LC and Zheng B: Phosphorylation of
BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation.
Mol Cell. 52:161–172. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rothenberg SM, Daniels GH and Wirth LJ:
Redifferentiation of iodine-refractory BRAF V600E-Mutant metastatic
papillary thyroid cancer with dabrafenib-response. Clin Cancer Res.
21:5640–5641. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Noble PW, Barkauskas CE and Iang D:
Pulmonary fibrosis: Patterns and perpetrators. J Clin Invest.
122:2756–2762. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Amara N, Goven D, Prost F, Muloway R,
Crestani B and Boczkowski J: NOX4/NADPH oxidase expression is
increased in pulmonary fibroblasts from patients with idiopathic
pulmonary fibrosis and mediates TGFbeta1-induced fibroblast
differentiation into myofibroblasts. Thorax. 65:733–738. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Udell CM, Rajakulendran T, Sicheri F and
Therrien M: Mechanistic principles of RAF kinase signaling. Cell
Mol Life Sci. 68:553–565. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Osborne JK, Zaganjor E and Cobb MH: Signal
control through Raf: In sickness and in health. Cell Res. 22:14–22.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roberts PJ and Der V: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Matallanas D, Birtwistle M, Romano D,
Zebisch A, Rauch J, von Kriegsheim A and Kolch W: Raf Family
Kinases: Old dogs have learned new tricks. Genes Cancer. 2:232–260.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gray-Schopfer V, Wellbrock C and Marais R:
Melanoma biology and new targeted therapy. Nature. 445:851–857.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
American Thyroid Association (ATA)
Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid
Cancer, . Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL,
Mandel SJ, Mazzaferri EL, McIver B, Pacini F, et al: Revised
American Thyroid Association management guidelines for patients
with thyroid nodules and differentiated thyroid cancer. Thyroid.
19:1167–1214. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tuttle RM, Ball DW, Byrd D, Dilawari RA,
Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, et al:
Thyroid carcinoma. J Natl Compr Canc Netw. 8:1228–1274. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brown RL, de Souza JA and Cohen EE:
Thyroid cancer: Burden of illness and management of disease. J
Cancer. 2:193–199. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cohen Y, Xing M, Mambo E, Guo Z, Wu G,
Trink B, Beller U, Westra WH, Ladenson PW and Sidransky D: BRAF
mutation in papillary thyroid carcinoma. J Natl Cancer Inst.
95:625–627. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ
and Qu JM: The BRAF mutation is predictive of aggressive
clinicopathological characteristics in papillary thyroid
microcarcinoma. Ann Surg Oncol. 1:3294–3300. 2010. View Article : Google Scholar
|
|
30
|
Kimura ET, Nikiforova MN, Zhu Z, Knauf JA,
Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in
thyroid cancer: Genetic evidence for constitutive activation of the
RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
Cancer Res. 63:1454–1457. 2003.PubMed/NCBI
|
|
31
|
Soares P, Trovisco V, Rocha AS, Lima J,
Castro P, Preto A, Máximo V, Botelho T, Seruca R and
Sobrinho-Simões M: BRAF mutations and RET/PTC rearrangements are
alternative events in the etiopathogenesis of PTC. Oncogene.
22:4578–4580. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vanden Borre P, McFadden DG, Gunda V,
Sadow PM, Varmeh S, Bernasconi M, Jacks T and Parangi S: The next
generation of orthotopic thyroid cancer models: immunocompetent
orthotopic mouse models of BRAF V600E-positive papillary and
anaplastic thyroid carcinoma. Thyroid. 24:705–714. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xing M, Alzahrani AS, Carson KA, Viola D,
Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, et al:
Association between BRAF V600E mutation and mortality in patients
with papillary thyroid cancer. JAMA. 309:1493–1501. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tang HC and Chen YC: Insight into
molecular dynamics simulation of BRAF(V600E) and potent novel
inhibitors for malignant melanoma. Int J Nanomedicine.
10:3131–3146. 2015.PubMed/NCBI
|
|
35
|
Eloy C, Santos J, Soares P and
Sobrinho-Simões M: The preeminence of growth pattern and
invasiveness and the limited influence of BRAF and RAS mutations in
the occurrence of papillary thyroid carcinoma lymph node
metastases. Virchows Arch. 459:265–276. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cheng S, Serra S, Mercado M, Ezzat S and
Asa SL: A high-throughput proteomic approach provides distinct
signatures for thyroid cancer behavior. Clin Cancer Res.
17:2385–2394. 2011. View Article : Google Scholar : PubMed/NCBI
|
